Medy-Tox - Public Comps and Valuation Multiples

Medy-Tox Overview

About Medy-Tox

Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.

Founded

2000

HQ

Employees

n/a

Website

medytox.com

Sectors

Biopharmaceuticals
BioTech

Financials

LTM Revenue $170M

LTM EBITDA $27.5M

EV

$579M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Medy-Tox Financials

As of November 2025, Medy-Tox reported last 12-month revenue of $170M and EBITDA of $27.5M.

In the same period, Medy-Tox generated $98.3M in LTM gross profit and $17.5M in net income.

See Medy-Tox valuation multiples based on analyst estimates

Medy-Tox P&L

In the most recent fiscal year, Medy-Tox reported revenue of $156M and EBITDA of $26.7M.

Medy-Tox expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Medy-Tox valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$170M	XXX	$156M	XXX	XXX	XXX
Gross Profit	$98.3M	XXX	$94.6M	XXX	XXX	XXX
Gross Margin	58%	XXX	61%	XXX	XXX	XXX
EBITDA	$27.5M	XXX	$26.7M	XXX	XXX	XXX
EBITDA Margin	16%	XXX	17%	XXX	XXX	XXX
EBIT	$19.8M	XXX	$13.8M	XXX	XXX	XXX
EBIT Margin	12%	XXX	9%	XXX	XXX	XXX
Net Profit	$17.5M	XXX	$11.5M	XXX	XXX	XXX
Net Margin	10%	XXX	7%	XXX	XXX	XXX
Net Debt	XXX	XXX	$22.6M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Medy-Tox including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $170M. EBITDA for the last twelve months was $27.5M. In the most recent fiscal year, Medy-Tox achieved $156M in revenue and $26.7M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$170M	Analyst estimates available to subscribers	$156M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$98.3M	Analyst estimates available to subscribers	$94.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	57.7% gross margin	Analyst estimates available to subscribers	60.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$27.5M	Analyst estimates available to subscribers	$26.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	16.2% EBITDA margin	Analyst estimates available to subscribers	17.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$19.8M	Analyst estimates available to subscribers	$13.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	11.6% EBIT margin	Analyst estimates available to subscribers	8.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$17.5M	Analyst estimates available to subscribers	$11.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	10.3% net profit margin	Analyst estimates available to subscribers	7.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$22.6M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Medy-Tox

This financial data table provides comprehensive performance metrics for Medy-Tox, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Medy-Tox generated $170M in revenue over the last twelve months.
The company achieved $27.5M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $98.3M.
Net income over the last twelve months reached $17.5M.

Fiscal Year Performance

In the most recent fiscal year, Medy-Tox reported $156M in total revenue.
Fiscal year EBITDA was $26.7M.
The company maintained a gross profit margin of 60.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 17.1%.
Net profit margin reached 7.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Medy-Tox. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Medy-Tox Stock Performance

Medy-Tox has current market cap of KRW 834B (or $568M), and EV of KRW 851B (or $579M).

Market Cap Evolution

Medy-Tox Stock Data

As of December 4, 2025, Medy-Tox's stock price is KRW 126800 (or $86).

See Medy-Tox trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$579M	$568M	XXX	XXX	XXX	XXX	$2.36

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Medy-Tox Valuation Multiples

Medy-Tox's trades at 3.7x EV/Revenue multiple, and 21.7x EV/EBITDA.

See valuation multiples for Medy-Tox and 15K+ public comps

Medy-Tox Financial Valuation Multiples

As of December 4, 2025, Medy-Tox has market cap of $568M and EV of $579M.

Equity research analysts estimate Medy-Tox's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Medy-Tox has a P/E ratio of 32.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$568M	XXX	$568M	XXX	XXX	XXX
EV (current)	$579M	XXX	$579M	XXX	XXX	XXX
EV/Revenue	3.4x	XXX	3.7x	XXX	XXX	XXX
EV/EBITDA	21.1x	XXX	21.7x	XXX	XXX	XXX
EV/EBIT	29.3x	XXX	41.8x	XXX	XXX	XXX
EV/Gross Profit	5.9x	XXX	n/a	XXX	XXX	XXX
P/E	32.5x	XXX	49.2x	XXX	XXX	XXX
EV/FCF	48.0x	XXX	47.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Medy-Tox Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Medy-Tox Margins & Growth Rates

Medy-Tox's last 12 month revenue growth is 13%

Medy-Tox's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Medy-Tox's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medy-Tox's rule of X is 48% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Medy-Tox and other 15K+ public comps

Medy-Tox Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	13%	XXX	12%	XXX	XXX	XXX
EBITDA Margin	16%	XXX	17%	XXX	XXX	XXX
EBITDA Growth	30%	XXX	10%	XXX	XXX	XXX
Rule of 40	28%	XXX	30%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	48%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	23%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	13%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	52%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial